Discovery
Pre-clinical
Phase 1
Phase 2

Overview

Symphogen by Servier has six immuno-oncology product candidates under development, four in Phase 1 trials (Sym021, Sym022, Sym023 and Sym024), one is in IND enabling phase (Sym025) and one in the late discovery phase (Sym026).

Currently, the majority of our research activities are in immuno-oncology and focused on identifying antibodies against novel targets to mobilize the immune system to fight tumors.

Target
Undisclosed